Acquisition history Discuva was acquired by Summit Therapeutics in 2018 for £10m cash plus shares, indicating a history of exits and potential interest from larger pharma and investor groups in its antibiotic platform.

Antibiotic focus As a Cambridge UK based Next Generation antibiotic discovery company with proprietary genomic approaches, Discuva presents an opportunity for collaboration or licensing of novel targets and platforms to accelerate development of drug-resistant pathogen therapies.

Small team, high specialization With 11-50 employees and a niche, high-skill scientific team, sales approaches can emphasize strategic partnerships, contract research, and selective licensing rather than full-scale strategic alliances.

Financial profile Revenue is under 1 million with funding around 1.9 million, suggesting a runway window for strategic partnerships, non-dilutive or milestone-driven deals, and potential co-development financing arrangements.

Industry positioning Benchmarking against peers with similar profiles shows potential for collaboration with biotech CROs, genomics-enabled drug discovery platforms, and translational research partners seeking next-gen antibiotic capabilities and access to innovative discovery platforms.